1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
HeXun Biosciences Co Ltd

HeXun Biosciences Co Ltd

TTPEX:6986
43.80
TWD
-0.85
(-1.90%)
2.51EPS
18.40P/E
2.42BMarket Cap
Mar 12Next Earn
HeXun Biosciences Co Ltd
TPEX:6986
(Taipei Exchange)

Recent

price

43.80

P/E

ratio

18.40

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
1.32
2.88
6.23
6.37
6.67
Revenue per Share
- -
-1.41
-0.14
0.74
3.2
2.43
2.52
Basic EPS, GAAP
- -
-1.16
0.27
0.45
1.82
2.94
2.87
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.91
4.67
6.84
10.29
13.49
16.12
20.5
Book Value per Share
3.86
4.63
5.95
9.55
12.91
15.67
20.16
Tangible Book Value per Share
46
31
38
45
46
46
46
Basic Weighted Avg Shares
- -
- -
49
131
286
293
308
Sales/Revenue/Turnover
- -
- -
-18.15
20.96
54.37
40.24
42.36
Operating Margin (%)
- -
12
15
20
25
29
31
Depreciation Expense
- -
-43
-5
33
147
112
116
Net Income, GAAP
- -
- -
- -
- -
8.82
11.13
17.62
Effective Tax Rate (%)
- -
- -
-10.49
25.65
51.4
38.16
37.74
Profit Margin (%)
67
86
191
334
429
547
878
Working Capital
74
71
67
67
32
33
31
LT Debt
180
215
315
473
621
742
1,069
Total Equity
- -
- -
- -
5.9
23.38
14.36
11.58
Return on Invested Capital (%)
- -
- -
- -
7.62
24.74
15.75
12.85
Return on Capital (%)
- -
-21.79
-1.96
8.5
26.92
16.43
13.26
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
33
32
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
52
Market Capitalization
2,898
2,654
2,416

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
610
626
957
Cash, Cash Equivalents & STI
510
529
829
Accounts Receivable, Net
74
72
93
Inventories
6
9
10
Total Current Liabilities
63
49
79
Payables & Accruals
- -
- -
- -
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
33.41%
19.5%
Free Cash Flow
- -
- -
61.48%
Net Income, GAAP
- -
- -
-23.99%
Sales/Revenue/Turnover
- -
- -
2.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
70
83
286
2025
51
101
57
85
293
2026
73
94
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.71
0.81
3.2
2025
0.29
1.04
0.29
0.8
2.43
2026
0.6
0.83
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
HeXun Biosciences Co., Ltd. operates as a biotechnology company primarily engaged in the research, development, manufacture, and sale of innovative biopharmaceutical products and medical technologies. Its core products include recombinant protein drugs, monoclonal antibodies, diagnostic reagents, biopharmaceutical raw materials, and related pharmaceutical preparations. The company focuses on products serving oncology, autoimmune diseases, infectious diseases, and other critical therapeutic areas. HeXun Biosciences targets healthcare institution clients, pharmaceutical companies, and research entities primarily within China but with expanding international market interests. Founded in 2017 and headquartered in China, HeXun Biosciences has strengthened its R&D capabilities and product pipeline through strategic collaborations and capital investments in the last two years. Notably, it has entered partnerships to enhance its biologics manufacturing technologies and expand its diagnostics portfolio. The company also recently launched new biosimilar drugs and advanced diagnostic kits aimed at improving disease detection and treatment efficacy. These developments reflect its ongoing strategic emphasis on integrating cutting-edge biotechnologies with commercial-scale production to accelerate market presence and innovation leadership. HeXun Biosciences operates within the biotechnology and pharmaceutical industry segments, focusing on biopharmaceutical innovation, production, and medical diagnostics. The company serves hospitals, clinical laboratories, pharmaceutical developers, and research organizations, aiming to meet the rising demand for biologics and health technology solutions. With a growing product portfolio, recent technological advancements, and enhanced manufacturing capacity, HeXun Biosciences continues expanding its footprint in the Asia-Pacific region and beyond, underpinning its role as a key player in China's life sciences sector.